Decoding how Korean beauty becomes global business.

K-Beauty clinical trials have devolved into a profit-driven circus where testing labs unbundle basic device metrics to inflate fees, while subject recycling and data manipulation threaten scientific validity. Domestic brands overspend on superficial device scores, whereas fast-growing brands opt for cost-effective user surveys. Overseas, lax clinical data poses catastrophic legal risks under post-market compliance systems like MoCRA (US) and CPNP (Europe).

Nothing in an American refusal notice for a Korean cosmetic is about chemistry. In FY2025, 69 per cent of Korea's US FDA cosmetics import refusals came down to labelling, and the same month that Korea's own regulator published its August enforcement record, five of its nine actions were for advertising liable to be mistaken for medicine. The compliance failure that actually stops Korean cosmetics, in both jurisdictions, is the sentence on the label — not the formula in the ja

The FDA’s historic approval of bemotrizinol (BEMT) marks the first new sunscreen ingredient in the U.S. since 1999. While this adds a game-changing UV filter to the market, it presents complex regulatory hurdles under MoCRA for global brands. Discover the strategic formulation, supply chain, and compliance shifts required for K-Beauty to legally scale in the U.S. sun care sector.